secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-067476
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology reports Phase 2 mCRC data: ORR 72.2% vs 43.2% SoC, PFS HR 0.37; plans registrational program
--------------------------------------------------------------------------------

- Phase 2 CRDF-004: ORR 72.2% vs 43.2% combined SoC; PFS HR 0.37 (p<0.05) for 30 mg onvansertib + FOLFIRI/bev in first-line RAS-mutated mCRC.
- Plans to advance 30 mg dose into registrational program; detailed data and FDA discussions expected H1 2026.
- Cash $58.3M as of Dec 31, 2025; funds operations into Q1 2027. Total op ex $49.6M, slight increase from $49.3M in 2024.
- Executive changes: Mani Mohindru appointed interim CEO; Brigitte Lindsay promoted to CAO; search for permanent CEO/CFO ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526067476/0001193125-26-067476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526067476/crdf-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-067476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer